Head to Head Analysis: Evolva (OTCMKTS:ELVAF) versus Cybin (OTCMKTS:CYBN)

Evolva (OTCMKTS:ELVAF) and Cybin (OTCMKTS:CYBN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional and Insider Ownership

22.0% of Evolva shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Evolva and Cybin, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolva	0	0	0	0	0.00
Cybin	0	0	1	0	3.00

Profitability

This table compares Evolva and Cybin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evolva	N/A	N/A	N/A
Cybin	N/A	-93.17%	-84.68%

Earnings & Valuation

This table compares Evolva and Cybin”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolva	N/A	N/A	N/A	C($0.08)	-11.25
Cybin	$680,000.00	212.24	-$35.93 million	($4.38)	-1.53

Evolva has higher earnings, but lower revenue than Cybin. Evolva is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Summary

Evolva beats Cybin on 5 of the 9 factors compared between the two stocks.

About Evolva

Evolva Holding SA is in the process of liquidation of its remaining assets. Previously, the company was engaged in discovery, research, development, and commercialization of nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. The company was founded in 2004 and is headquartered in Reinach, Switzerland.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.